About Bioline  All Journals  Testimonials  Membership  News  Donations

Tropical Journal of Pharmaceutical Research
Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria
ISSN: 1596-5996
EISSN: 1596-9827
Vol. 14, No. 8, 2015, pp. 1421-1425
Bioline Code: pr15186
Full paper language: English
Document type: Research Article
Document available free of charge

Tropical Journal of Pharmaceutical Research, Vol. 14, No. 8, 2015, pp. 1421-1425

 en Evaluation of Anti-Cancer Properties of Pegylated Ethosomal Paclitaxel on Human Melanoma Cell Line SKMEL- 3
Eskolaky, Elham Bagheri; Ardjmand, Mehdi & Akbarzadeh, Azim


Purpose: To prepare pegylated ethosomal Paclitaxel® by reverse phase evaporation technique, and evaluate its cytotoxic effect on SK-MEL-3 cell line.
Methods: Nanodrug was prepared by reverse phase evaporation technique. The characteristics of the nanoparticles were evaluated by a zetasizer and scanning electron microscopy (SEM). Drug loading and encapsulation efficiency as well as paclitaxel® release were determined spectrophotometerically at 227 nm while the cytotoxicity of the pegylated ethosomal nanoencapsulated Paclitaxel® was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay on SK-MEL-3 cell line.
Results: The mean diameter and zeta potential of drug-loaded pegylated ethosomal particles and blank pegylated ethosomes were 138.1 ± 2.7 nm and −13.1 mV, and 102.3 ± 2.1 nm and −19.2 mV, respectively, while drug loading and encapsulation efficiency were 2.82 ± 0.27 and 96 ± 1.27%, respectively. The drug release pattern indicates that the half-life (t1/2) of the nanodrug was approximately twice that of the free drug for both static and dynamic release. Toxicological results indicate approx. 4.5-fold cytotoxicity against SK-MEL-3 cell line compared with the free drug.
Conclusion: This study shows that pegylated ethosomal Paclitaxel® is significantly considerably more toxic than the free drug on SK-MEL-3 cell line, thus making it an potential alternative to the standard therapy. It is, however, necessary to evaluate the nanoformulation in vivo.

Paclitaxel®; Ethosome; Reverse phase evaporation; Pegylated; Cytotoxicity; Nanoparticles; Drug release

© Copyright 2015 - Tropical Journal of Pharmaceutical Research
Alternative site location:

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2022, Site last up-dated on 19-Jan-2022.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Internet Data Center of Rede Nacional de Ensino e Pesquisa, RNP, Brazil